Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

Clinical evidences have demonstrated limited efficacy of HER2-targeted therapies in patients with gastric cancer (GC). Here the authors show that survival benefit to anti-HER2 antibody Trastuzumab is reduced in GC patients with high levels of the caveolin-1 and that, in preclinical cancer models, an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Patrícia M. R. Pereira, Komal Mandleywala, Sébastien Monette, Melissa Lumish, Kathryn M. Tully, Sandeep Surendra Panikar, Mike Cornejo, Audrey Mauguen, Ashwin Ragupathi, Nai C. Keltee, Marissa Mattar, Yelena Y. Janjigian, Jason S. Lewis
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Portfolio 2022-05-01
Colección:Nature Communications
Acceso en línea:https://doi.org/10.1038/s41467-022-30142-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares